MacroGenics Inc (MGNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MacroGenics Inc (MGNX) has a cash flow conversion efficiency ratio of 0.774x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.02 Million) by net assets ($55.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MacroGenics Inc balance sheet independence to measure how much of total assets are equity-financed.
MacroGenics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how MacroGenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MGNX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
MacroGenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MacroGenics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thirumalai Chemicals Limited
NSE:TIRUMALCHM
|
-0.175x |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
N/A |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
0.000x |
|
Signature International Bhd
KLSE:7246
|
0.018x |
|
Clarke Inc.
TO:CKI
|
0.009x |
|
ALTEO ENERG.NYIL M.UF125
F:54O
|
N/A |
|
Global Water Resources Inc
NASDAQ:GWRS
|
0.097x |
|
GoldMining Inc
TO:GOLD
|
-0.026x |
Annual Cash Flow Conversion Efficiency for MacroGenics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of MacroGenics Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is MacroGenics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $55.59 Million | $-81.04 Million | -1.458x | -147.45% |
| 2024-12-31 | $116.06 Million | $-68.37 Million | -0.589x | -14.97% |
| 2023-12-31 | $152.61 Million | $-78.20 Million | -0.512x | +16.31% |
| 2022-12-31 | $142.01 Million | $-86.96 Million | -0.612x | -2.01% |
| 2021-12-31 | $239.62 Million | $-143.83 Million | -0.600x | -58.72% |
| 2020-12-31 | $295.88 Million | $-111.90 Million | -0.378x | +35.04% |
| 2019-12-31 | $230.63 Million | $-134.27 Million | -0.582x | +7.72% |
| 2018-12-31 | $242.88 Million | $-153.23 Million | -0.631x | -1410.61% |
| 2017-12-31 | $299.24 Million | $14.40 Million | 0.048x | +129.62% |
| 2016-12-31 | $268.75 Million | $-43.68 Million | -0.163x | -272.78% |
| 2015-12-31 | $313.34 Million | $-13.66 Million | -0.044x | +83.86% |
| 2014-12-31 | $121.29 Million | $-32.76 Million | -0.270x | -50.40% |
| 2013-12-31 | $78.91 Million | $-14.17 Million | -0.180x | -122.48% |
| 2012-12-31 | $-8.24 Million | $-6.58 Million | 0.799x | +306.75% |
| 2011-12-31 | $-17.48 Million | $6.76 Million | -0.386x | -- |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more